NEW YORK, NY / ACCESSWIRE / February 2, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Minerva Neurosciences, Inc. (NASDAQ:NERV)
CONTACT JAKUBOWITZ ABOUT NERV:
https://claimyourloss.com/securities/minerva-neurosciences-inc-loss-submission-form/?id=12624&from=1
Class Period: May 15, 2017 - November 30, 2020
Lead Plaintiff Deadline : February 8, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the "end-of-Phase 2" meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be "highly unlikely" to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to "substantial review issues" because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Tricida, Inc. (NASDAQ:TCDA)
CONTACT JAKUBOWITZ ABOUT TCDA:
https://claimyourloss.com/securities/tricida-inc-loss-submission-form/?id=12624&from=1
Class Period: September 4, 2019 - October 28, 2020
Lead Plaintiff Deadline: March 8, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Tricida's NDA for veverimer was materially deficient; (ii) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Bit Digital, Inc. (NASDAQ:BTBT)
CONTACT JAKUBOWITZ ABOUT BTBT:
https://claimyourloss.com/securities/bit-digital-inc-loss-submission-form/?id=12624&from=1
Class Period: December 21, 2020 - January 8, 2021
Lead Plaintiff Deadline: March 22, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) that Bit Digital overstated the extent of its a bitcoin mining operation; and (2) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law